Sept 16 (Reuters) - The U.S. Food and Drug
Administration has sent a warning letter to telehealth firm Hims
& Hers Health ( HIMS ) regarding its compounded versions of Novo
Nordisk's diabetes drug Ozempic and weight-loss
treatment Wegovy.